3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Melanoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Anus Neoplasms
1
Interventions
Fluorouracil
267
Oxaliplatin
266
Capecitabine
225
Leucovorin
209
Irinotecan
151
Radiotherapy
132
Bevacizumab
112
Cetuximab
81
Folfox protocol
49
Surgical Procedures, Operative
44
Radiation
41
Drug Therapy
41
Neoadjuvant Therapy
40
Chemoradiotherapy
33
Chemotherapy, Adjuvant
32
Panitumumab
27
XELOX
25
Magnetic Resonance Spectroscopy
22
Radiotherapy, Intensity-Modulated
21
Floxuridine
17
Biopsy
16
Nivolumab
15
Gemcitabine
15
Early Intervention, Educational
15
pembrolizumab
14
Laparoscopy
14
IFL protocol
14
Celecoxib
14
trifluridine tipiracil drug combination
13
Gene Expression Profiling
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Rectal Neoplasms
×
nanocis
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled